Patents by Inventor Carola Steiger

Carola Steiger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230037742
    Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.
    Type: Application
    Filed: April 2, 2021
    Publication date: February 9, 2023
    Applicant: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Peter KUFER, Tobias RAUM, Roman KISCHEL, Ralf Lutterbüse, Patrick HOFFMANN, Doris RAU, Susanne MANGOLD, Matthias KLINGER, Evelyne SCHALLER, Susanne HAUSMANN, Petra FLUHR, Carola STEIGER
  • Patent number: 11472886
    Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: October 18, 2022
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Peter Kufer, Tobias Raum, Roman Kischel, Ralf Lutterbüse, Patrick Hoffmann, Doris Rau, Susanne Mangold, Matthias Klinger, Evelyne Schaller, Susanne Hausmann, Petra Fluhr, Carola Steiger
  • Publication number: 20210277143
    Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.
    Type: Application
    Filed: April 2, 2021
    Publication date: September 9, 2021
    Applicant: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Peter KUFER, Tobias RAUM, Roman KISCHEL, Ralf Lutterbüse, Patrick HOFFMANN, Doris RAU, Susanne MANGOLD, Matthias KLINGER, Evelyne SCHALLER, Susanne HAUSMANN, Petra FLUHR, Carola STEIGER
  • Publication number: 20210269550
    Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.
    Type: Application
    Filed: April 2, 2021
    Publication date: September 2, 2021
    Applicant: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Peter KUFER, Tobias RAUM, Roman KISCHEL, Ralf Lutterbüse, Patrick HOFFMANN, Doris RAU, Susanne MANGOLD, Matthias KLINGER, Evelyne SCHALLER, Susanne HAUSMANN, Petra FLUHR, Carola STEIGER
  • Publication number: 20190169310
    Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain anti-body molecule.
    Type: Application
    Filed: June 27, 2018
    Publication date: June 6, 2019
    Inventors: Peter Kufer, Tobias Raum, Roman Kischel, Ralf Lutterbüse, Patrick Hoffmann, Doris Rau, Susanne Mangold, Matthias Klinger, Evelyne Schaller, Susanne Hausmann, Petra Fluhr, Carola Steiger
  • Patent number: 9587036
    Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: March 7, 2017
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Peter Kufer, Ralf Lutterbuese, Matthias Klinger, Petra Fluhr, Doris Rau, Susanne Hausmann, Carola Steiger, Tobias Raum, Patrick Hoffmann, Roman Kischel, Evelyne Schaller, Susanne Mangold
  • Publication number: 20110293619
    Abstract: The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain anti-body molecule.
    Type: Application
    Filed: October 1, 2009
    Publication date: December 1, 2011
    Inventors: Peter Kufer, Tobias Raum, Roman Kischel, Ralf Lütterbuse, Patrick Hoffmann, Doris Rau, Susanne Mangold, Matthias Klinger, Evelyne aschaller, Susanne Hausmann, Petra Fluhr, Carola Steiger